"Devyser reports yet another quarter of record sales and strong gross margins. The positive sales and margin trend remains stable.
We are following the strategic plan we launched nearly…
Devyser announces its decision to establish a CLIA lab in Atlanta, Georgia, USA. By operating a CLIA lab, Devyser obtains complete control of the selling process, including reimbursement…
On Thursday November 10, at 08.30 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2022 interim report (which will have been published earlier on November 10, at…
Devyser today announces the appointment of John Murad as Vice President and General Manager for Devyser US. He will be responsible for all Devyser operations in North America. John Murad…
Devyser Diagnostics AB (publ) (“Devyser”) has appointed Carnegie Investment Bank AB (publ) (”Carnegie”) as liquidity provider for the company’s shares listed on Nasdaq First North Growth…
Devyser has today been certified under the new, more comprehensive IVD Regulation that came into force on May 26, 2022. The certification, issued by the notified body TÜV SÜD, covers…
"Devyser reported another quarter of strong organic growth, which again saw record-breaking sales. The gross margin remained high. Both sales and margins have the potential for further…
On September 1, Camilla Wiberg will take up the newly established position as Chief HR Officer (CHRO) and become a member of the Devyser group management. In Devyser’s current growth…
On Wednesday August 24, at 09.00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2022 interim report (which will have been published earlier on August 24, at 08.00…
Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early…
